News - Myeloma Patients Europe

Latest News

EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patients

November 20, 2024

On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) recommended adding a new indication for isatuximab, a monoclonal antibody treatment marketed by Sanofi as Sarclisa ®. The CHMP is the European…

MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union level

October 29, 2024

Yesterday 28 October, MPE provided feedback, as part of a public consultation open to all categories of stakeholders, on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union level.…

During European Myeloma Day, MPE highlights the importance of improving access to clinical trials

September 27, 2024

Brussels, 27 September 2024 – Today is European Myeloma Day, a date dedicated to raising awareness of key issues affecting myeloma patients across Europe. This year, Myeloma Patients Europe (MPE) is highlighting the role of…

EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplant

September 26, 2024

On 19 September the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for daratumumab (Darzalex®, commercialised by Janssen). The new indication is a…

A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and Wales

July 17, 2024

After the approval of the first bispecific antibody for myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom’s public body for medicine appraisals) approved today, 16 July 2024, a…

The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and Wales

July 9, 2024

On the 21st of June NICE, the United Kingdom’s public body for medicine appraisals, approved the use of the UK’s first bispecific drug for myeloma, elranatamab. Evidence from an ongoing clinical trial showed that…

MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)

June 26, 2024

The EU Health Technology Assessment (HTA) Regulation (EU HTAR) entered into force in January 2022 and will be applied starting in January 2025. It aims to improve the availability of medicines and certain medical devices by establishing…

European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

April 23, 2024

The European Commission has approved marketing authorisation extension for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD –…

October

November 2024

December

MO
TU
WE
TH
FR
SA
SU

28
29
30
31
1
2
3

4
5
6
7
8
9
10

11
12
13
14
15
16
17

18
19
20
21
22
23
24

25
26
27
28
29
30
1

Latest News

November 2024

Events for November

1st

Events for November

2nd

Events for November

3rd

Events for November

4th

Events for November

5th

Events for November

6th

Events for November

7th

Events for November

8th

Events for November

9th

Events for November

10th

Events for November

11th

Events for November

12th

Events for November

13th

Events for November

14th

Events for November

15th

Events for November

16th

Events for November

17th

Events for November

18th

Events for November

19th

Events for November

20th

Events for November

21st

Events for November

22nd

Events for November

23rd

Events for November

24th

Events for November

25th

Events for November

26th

Events for November

27th

Events for November

28th

Events for November

29th

Events for November

30th

Myeloma Patients Europe AISBL

PopUp